Phase II Trial of Stereotactic Ablative Radiation Therapy (SABR) in Patients with Oligoprogressive Small Cell Lung Carcinoma (SCLC)
Immunotherapy has improved management of small-cell lung cancer (SCLC) but many patients relapse. If SCLC remains after treatment and is limited to a few areas, physicians may recommend switching treatments to target these recurrent tumors. However, new treatments may have additional side effects or unclear benefits. Many patients and doctors want to continue their first-line therapy or current immunotherapy treatments. Patients in our clinical trial with SCLC and limited disease spread will stay on their current immunotherapy regimen and receive SBRT, a form of targeted radiation. We aim to determine if this can increase the time patients stay on their original immunotherapy. We will monitor patients for any unexpected side effects and changes to quality of life. We will also evaluate responses to treatment and disease recurrence. We aim to determine if this treatment plan will decrease the chances of further disease spread, enhance overall cancer control and improve survival.
